Drug-eluting stents compared to bare-metal stents improve short-term survival in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a nationwide prospective analysis of the AMIS Plus registry.
Details
State: Public
Version: Final published version
Serval ID
serval:BIB_4F7C95E9EFC8
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Drug-eluting stents compared to bare-metal stents improve short-term survival in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a nationwide prospective analysis of the AMIS Plus registry.
Journal
Kardiologia Polska
Contributor(s)
Lessing P., Hess F., Simon R., Hangartner PJ., Hufschmid U., Hunziker P., Jeger R., Grädel C., Hornig B., Schönfelder A., Windecker S., Loretan P., Schläpfer H., Roethlisberger C., Mang G., Ryser D., Niedermaier G., Kistler W., Droll A., Hongler T., Stäuble S., Freiwald G., Schmid HP., Stauffer JC., Cook S., Bietenhard K., Keller PF., Roffi M., Oertli B., Schönenberger R., Schmidli M., Federspiel B., Schröpfer D., Weiss EM., Weber K., Zender H., Steffen C., Poepping I., Hugi A., Frei J., Koltai E., Iglesias JF., Pedrazzini G., Erne P., Cuculi F., Heimes T., Pagnamenta A., Urban P., Stettler C., Repond F., Widmer F., Heimgartner C., Polikar R., Bassetti S., Iselin HU., Giger M., Egger P., Kaeslin T., Frey R., Fischer A., Herren T., Caduff B., Girod G., Grêt A., Schönenberger R., Vogel R., Niggli B., Rickli H., Yoon SI., Stoller U., Bächli E., Graber M., Vontobel H., Eriksson U., Haller A., Fischer T., Peter M., Gasser S., Fatio R., Vogt M., Ramsay D., Bertel O., Maggiorini M., Eberli F., Fischler M., Christen S., Buchholz S.
ISSN
0022-9032 (Print)
ISSN-L
0022-9032
Publication state
Published
Issued date
2014
Peer-reviewed
Oui
Volume
72
Number
4
Pages
315-323
Language
english
Abstract
BACKGROUND: Recently, it has been suggested that the type of stent used in primary percutaneous coronary interventions (pPCI) might impact upon the outcomes of patients with acute myocardial infarction (AMI). Indeed, drug-eluting stents (DES) reduce neointimal hyperplasia compared to bare-metal stents (BMS). Moreover, the later generation DES, due to its biocompatible polymer coatings and stent design, allows for greater deliverability, improved endothelial healing and therefore less restenosis and thrombus generation. However, data on the safety and performance of DES in large cohorts of AMI is still limited.
AIM: To compare the early outcome of DES vs. BMS in AMI patients.
METHODS: This was a prospective, multicentre analysis containing patients from 64 hospitals in Switzerland with AMI undergoing pPCI between 2005 and 2013. The primary endpoint was in-hospital all-cause death, whereas the secondary endpoint included a composite measure of major adverse cardiac and cerebrovascular events (MACCE) of death, reinfarction, and cerebrovascular event.
RESULTS: Of 20,464 patients with a primary diagnosis of AMI and enrolled to the AMIS Plus registry, 15,026 were referred for pPCI and 13,442 received stent implantation. 10,094 patients were implanted with DES and 2,260 with BMS. The overall in-hospital mortality was significantly lower in patients with DES compared to those with BMS implantation (2.6% vs. 7.1%,p < 0.001). The overall in-hospital MACCE after DES was similarly lower compared to BMS (3.5% vs. 7.6%, p < 0.001). After adjusting for all confounding covariables, DES remained an independent predictor for lower in-hospital mortality (OR 0.51,95% CI 0.40-0.67, p < 0.001). Since groups differed as regards to baseline characteristics and pharmacological treatment, we performed a propensity score matching (PSM) to limit potential biases. Even after the PSM, DES implantation remained independently associated with a reduced risk of in-hospital mortality (adjusted OR 0.54, 95% CI 0.39-0.76, p < 0.001).
CONCLUSIONS: In unselected patients from a nationwide, real-world cohort, we found DES, compared to BMS, was associated with lower in-hospital mortality and MACCE. The identification of optimal treatment strategies of patients with AMI needs further randomised evaluation; however, our findings suggest a potential benefit with DES.
AIM: To compare the early outcome of DES vs. BMS in AMI patients.
METHODS: This was a prospective, multicentre analysis containing patients from 64 hospitals in Switzerland with AMI undergoing pPCI between 2005 and 2013. The primary endpoint was in-hospital all-cause death, whereas the secondary endpoint included a composite measure of major adverse cardiac and cerebrovascular events (MACCE) of death, reinfarction, and cerebrovascular event.
RESULTS: Of 20,464 patients with a primary diagnosis of AMI and enrolled to the AMIS Plus registry, 15,026 were referred for pPCI and 13,442 received stent implantation. 10,094 patients were implanted with DES and 2,260 with BMS. The overall in-hospital mortality was significantly lower in patients with DES compared to those with BMS implantation (2.6% vs. 7.1%,p < 0.001). The overall in-hospital MACCE after DES was similarly lower compared to BMS (3.5% vs. 7.6%, p < 0.001). After adjusting for all confounding covariables, DES remained an independent predictor for lower in-hospital mortality (OR 0.51,95% CI 0.40-0.67, p < 0.001). Since groups differed as regards to baseline characteristics and pharmacological treatment, we performed a propensity score matching (PSM) to limit potential biases. Even after the PSM, DES implantation remained independently associated with a reduced risk of in-hospital mortality (adjusted OR 0.54, 95% CI 0.39-0.76, p < 0.001).
CONCLUSIONS: In unselected patients from a nationwide, real-world cohort, we found DES, compared to BMS, was associated with lower in-hospital mortality and MACCE. The identification of optimal treatment strategies of patients with AMI needs further randomised evaluation; however, our findings suggest a potential benefit with DES.
Pubmed
Web of science
Create date
05/08/2015 10:31
Last modification date
20/08/2019 14:05
Usage data
